{"name":"Ribozyome","slug":"ribozyome","ticker":"","exchange":"","domain":"","description":"Ribozyome is a biotechnology company focused on developing ribozyme-based therapies. The company has one drug in its pipeline, an anti-FLT-1 ribozyme in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9oRlduMkVhWnVPMlJUQkNLcHhfUlR2d1paZlNfM2pEc0FYOS1LU3hkTVJTOVU5YW13dHh2S25aWjBicHQ3TjM4X29jbHlweHc3Mi0wNml1SmYtUTZ0X211NGFYYWw2ZWVxWktpYkhn0gFyQVVfeXFMT0p4ZlFLTjIyTXY3ZnY4RXQ4bXBQZkpkaXpMSTZDUWxoOHhqUjVrZ0l1WjNVMkoxT1RJcFZEZzcxeko3ZjQxeFBtOVIzTU1kSkRlNGltaG9xR1pYdHc1dWZkMk5JVFJjSFdGQl9SaDdMZDFB?oc=5","date":"2025-12-08","type":"trial","source":"koreabiomed.com","summary":"Korean gene therapy RZ-001 reports encouraging phase 1 data in brain cancer - koreabiomed.com","headline":"Korean gene therapy RZ-001 reports encouraging phase 1 data in brain cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQa285ME1HYXgwSEh3Y2J5cXBDNE5EVUJxanhyZ0I2b3JiSnNLaVM3OE03SENtaHJVYjRkYXZKajBhNGdKRlM4ODB4RmhVWXR1VE1BZExweWtFSnNlclNRaHpHRnRHNmVheXdnOGgtSkJiVHkzVlpOclZzc0FUb2oxQTNWdm9qNTQ5YW1zbDVILXZKN2VrMlhzZnA3YUZhS1Fw?oc=5","date":"2025-05-16","type":"pipeline","source":"Fierce Biotech","summary":"Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact - Fierce Biotech","headline":"Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcTJCYWlVaWRQUGJMU005dmdjR0hwVzY3dUE5c0FOYzFYZVVwXzlKemROV3NrS0EwdFBNbGNEb0ZMZzl2ZURpSGJWNXp2S0xTZENaM3ZUOUNoQzhHeVZxdVJoRjVpQnJ0WnFYbTl3em41ajRFUmhuZUxWbEZ4T2w2TUtPZWxJS054aTVqQ0xTdE1PTjBjbUx3MzBtS0JFeENMa0Y4bUtkdnA3d1pjc0hfNmE3bVJTUQ?oc=5","date":"2025-05-16","type":"pipeline","source":"BioSpace","summary":"Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline - BioSpace","headline":"Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOeklqeU5ZWkJUM3hqaktjcXN5ZzczaktBSWIyUlg2YV9Eck4xX1haUVJCV09RWTFJRUJaVnFsVnlMWjM5MFp3SzM0ZVpBQ2dyZlFpc1hzdEltMHdiV1JMUG1fRjFrY0VoNlhYbDY1OWJOSnU5elBTS19XWlY0RFpSTXFuUHQ3X2pKVDFKUXQ4OA?oc=5","date":"2017-01-31","type":"trial","source":"Bioprocess Online","summary":"Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2 - Bioprocess Online","headline":"Ribozyme Pharmaceuticals Going Into Clinical Trials with Herzyme, Ribozyme Directed Against HER-2","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}